Given the invasive
and cost-intensive nature of tissue biopsies, there is a significant unmet need
for safer and more patient-friendly cancer diagnostics that are capable of
offering highly accurate, and actionable insights related to the disease.
To order this 350+
page report, which features 150+ figures and 200+ tables, please visit this link
The financial opportunity within the liquid biopsy and
other non-invasive cancer diagnostics market has been analyzed across the
following segments:
§
- ctDNA
- cfDNA
- CTCs
- Exosomes
- Others
§
- Diagnosis / Early Diagnosis
- Patient Monitoring
- Recurrence Monitoring
§
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Gastric Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
§
- Hospitals
- Research Institutes
- Others
§
- North America
- Europe
- Asia-Pacific
- Rest
of the World
The Liquid Biopsy and Other Non-Invasive
Cancer Diagnostics
Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as
CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers report features the following companies, which
we identified to be key players in this domain:
§
§
§
§
§
§
§
§
Press Release:
Variation 3 (Format 4)
Table of Contents
1.
Preface
4.
Non-Invasive Cancer Screening and Diagnosis
5. Market
Landscape
6.
Company Profiles
7.
Partnerships and Collaborations
8.
Funding and Investment Analysis
9. Liquid
Biopsy: Initiatives of Big Pharma Players
10. Key
Acquisition Targets
11.
Other Non-Invasive Cancer Diagnostics
12. Market
Sizing and Opportunity Analysis
13. Survey
Insights
14. Conclusion
15. Executive
Insights
16.
Appendix 1: Tabulated Data
17.
Appendix 2: List of Companies and Organizations
To purchase a copy,
please visit https://www.rootsanalysis.com/reports/view_document/liquid-biopsy-and-nicd-market/279.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
